Drug Profile
Recaticimab - Jiangsu Hengrui Medicine Co.
Alternative Names: SHR-1209Latest Information Update: 26 Dec 2023
Price :
$50
*
At a glance
- Originator Jiangsu Hengrui Medicine Co.
- Class Antihyperlipidaemics; Monoclonal antibodies
- Mechanism of Action PCSK9 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Hypercholesterolaemia; Hyperlipidaemia
Most Recent Events
- 11 Nov 2023 Efficacy and adverse events data from a phase III REMAIN-2 trial in Hypercholesterolaemia and Hyperlipidemia presented at the American Heart Association Scientific Sessions 2023 (AHA-2023)
- 13 Jan 2023 Jiangsu HengRui Medicine completes a phase III trial for Hypercholesterolaemia (In adults, In the elderly) in China (SC) (NCT04849000)
- 13 Jan 2023 Jiangsu HengRui Medicine completes a phase III trial for Hyperlipidemia (In adults, In the elderly) in China (SC) (NCT04849000)